5Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders : structured review of the literature. J Rheumatol, 2006,33 : 2124 -2131.
6Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomized controlled trials. Ann Rheum Dis ,2009,68 : 1177-1183.
7Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) ,2008,87:345 -364.
8Borhani Haghighi A. Treatment of neuro-Behcet' s disease: an update. Expert Rev Neurother,2009 ,9 :565-574.
9sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet' s disease-review and basis for recommendations. Rheumatology (Oxford) ,2007,46:736-741.
10Langford CA. Drug insight:anti-tumor necrosis factor therapies for the vasculitic diseases. Nat Clin Pract Rheumatol,2008,4:364-370.
3Brophy S, Mackay K, Al-Saidi A, et al. The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol, 2002, 29: 1236-1243.
4Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology (Oxford), 2004, 43: 1565- 1568.
5Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset,and disease expression. J Rheumatol, 2001, 28: 2283-2288.
6Georg Schett. Joint remodeling in inflammatory disease. Ann Rheum Dis, 2007, 66(Suppl 3): 42-44.
7Zochling J, Van HD, Burgos VR, et al. ASAS/EU LAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis, 2006, 65: 442-452.
8Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis, 2007, 66: 1072-1077.
9Pham T, Landewe R, van der Linden S, et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis, 2006, 65: 1620-1625.
10Gadsby K, Deighton C. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. Rheumatology (Oxford), 2007, 46: 439-441.
5Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study [ J ]. Arthritis Rheum, 2005,52 (3) :722-732.
6van Halm VP, Peters M J, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross- sectional study, the CARRE Investigation [ J ]. Ann Rheum Dis, 2009,68 ( 9 ) : 1395-1400.
7Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence- based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis[J]. Ann Rheum Dis, 2010,69(2) :325-331.
8Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis [ J ]. N Engl J Med, 1953,249 (14) :553-556.
9Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modi- fiable cardiovascular risk factors in patients with rheumatoid arthri- tis: comparison with control subjects from the multi-ethnic study of atheroselerosis[J]. Semin Arthritis Rheum, 2012,41(4) :535-544.
10Santos M J, Vinagre F, Silva JJ, et al. Cardiovascular risk profile in systemic lupus erythematosus and rheumatoid arthritis: a com- parative study of female patients [ J ]. Acta Reumatol Port, 2010, 35(3) :325-332.
